Dr Jordi Monés addresses at the 15th ISOPT the latest developments in the Lucerne and Rhine trials08/11/2019 · News
The Director del Institut de la Màcula, Dr Jordi Monés MD, PhD, was a protagonist at the prestigious ISOPT Clinical, held in Valencia on 7-9 November. One of his lectures focused on a review of the phase II clinical trials that tested the safety and efficacy of faricimab. These have given rise to two phase III clinical trials, Lucerne and Rhine, for exudative age-related macular degeneration (AMD) and diabetic macular oedema (DME), respectively
Valencia hosted the prestigious 15th International Symposium on Ocular Pharmacology and Therapeutics Clinical: The Retina Chapter (ISOPT Clinical), a meeting point for analysing pharmacological clinical therapies and treatments in ophthalmology that was held on November 7-9. During the first day, the Director of the Institut de la Màcula and ophthalmologist specialised in macula, retina and vitreous, Dr. Jordi Monés MD, PhD, reviewed the data obtained from the phase II clinical trials Avenue, Stairway and Boulevard. These tested the safety and efficacy of the drug faricimab with encouraging results that have enabled the design of phase III clinical trials in which the Institut de la Màcula is participating: Lucerne and Rhine, which are both led by the Roche pharmaceutical company.
Under the title “Simultaneous neutralization of angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) with faricimab: a review of the phase 2 clinical trials in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)”, Dr. Monés also reviewed the two clinical trials, whose recruitment processes have already concluded.
The principal aim of Lucerne, a multicentre, randomised and double-masked trial, is to demonstrate the efficacy and safety of faricimab in comparison with aflibercept. This is a trial that consists of the intravitreal administration of a new state-of the-art drug for the treatment of the exudative type of age-related macular degeneration (AMD).
Faricimab is the first bispecific monoclonal antibody designed for intravitreal use that combines the antiangiogenic action of the drugs currently used for the treatment of AMD with anti-inflammatory action, neutralising both VEGF and angiopoietin-2 in order to increase the interval between treatments.
With regards to the Rhine clinical trial, this assesses the efficacy and safety of faricimab administered through intravitreal injections in adult patients with vision loss due to diabetic macular oedema (DME), in comparison with administration of aflibercept.
In addition to this talk, Dr Jordi Mones MD, PhD also gave two other lectures as part of the 15th ISOPT Clinical, under the titles of “Review the pathogenesis of AMD and the pathways to CNV and GA” and “Novel gene therapy approaches for inherited retinal diseases”. Dr Lucía Lee Ferraro MD, PhD, the Institut de la Màcula’s specialist ophthalmologist, also attended the prestigious congress where she presented “Transplantation of human iPS cells-derived RPE cell suspension into the subretinal space of a swine model of geographic atrophy”. This is linked to the ADVANCE(CAT) project of which the Barcelona Macula Foundation forms part, together with the Universitat of Barcelona, the Centre of Regenerative Medicine in Barcelona (CMRB), the Leitat Foundation, Bioiberica, the Banc de Sang i Teixits (BST), Ferrer International, the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), the Bosch i Gimpera Foundation (FBiG) and the Health Sciences Research Institute of the Germans Trias i Pujol Foundation(IGTP).Diabetic macular oedemaExudative or wet AMD